Westminster,
CA – September 2, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable
technologies and a full-service environmental engineering company, today announced
an important milestone in its ongoing efforts to bring to market a safe and effective
antiviral disinfectant based on its patented CupriDyne® technology. In a
third-party study conducted by researchers at the Galveston National Laboratory
(GNL) at the University of Texas Medical Branch (UTMB), a modified CupriDyne
formula was shown to cause complete inactivation of SARS-CoV-2 (the COVID-19
virus) in 10 minutes – roughly the same performance observed with highly
concentrated bleach.
BioLargo had previously disclosed that its CupriDyne technology was proven capable of reducing SARS-CoV-2 titers by 99% after 30 minutes, with complete inactivation occurring after 60 minutes of CupriDyne exposure. Since that time, BioLargo scientists worked to modify the CupriDyne formula to achieve faster bacterial and viral inactivation in order to prepare to file for an EPA registration for a new disinfecting product (to be named) that is based on the CupriDyne technology. These new results indicate that those efforts were successful, and that the technology is now capable of total antiviral disinfection in 10 minutes against SARS-CoV-2.
BioLargo
President & CEO Dennis P. Calvert commented, “We believe that the future is
bright for our CupriDyne-based disinfectants. We intend to apply for registration
with the EPA once product designs are finalized. It is important to understand that we are
achieving these extraordinary results at a significantly lower concentration
than that of bleach in the same test protocol. We have retained a leading EPA
consulting firm to lead us in the EPA registration process and intend to move
ahead as soon as possible. These products are a great addition to our expanding
portfolio.”
About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and
environmental engineering solutions provider driven by a mission to “make life
better”. We feature unique disruptive
solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our
engineering division features experienced professional engineers dedicated to
integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our
industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features
CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which
eliminates the odor-causing compounds and VOCs rather than masking them, and is
now winning over leading companies in the solid waste handling and wastewater
industries and other industries that contend with malodors and VOCs. Our
subsidiary BioLargo Water (www.biolargowater.ca) develops
the Advanced Oxidation System "AOS," a disruptive industrial water
treatment technology designed to eliminate waterborne pathogens and
recalcitrant contaminants with better energy-efficiency and lower operational
costs than incumbent technologies. We are a minority stockholder of and technology
licensor to our subsidiary Clyra Medical which features its breakthrough
product Clyraguard ( www.clyramedical.com/clyraguard), an FDA
Registered, hospital grade disinfectant for personal protective equipment
including facemasks, proven 99.999% effective and safe for skin, as well as its
other products offering gentle solutions for chronic infected wounds to promote
infection control and regenerative tissue therapy.
About Galveston National Laboratory/UTMB
The Galveston National Laboratory (GNL) is a sophisticated
high containment research facility that serves as a critically important
resource in the global fight against infectious diseases. The GNL is located on
the campus of the University of Texas Medical Branch and operates under the umbrella
of UTMB’s Institute for Human Infections and Immunity.
Researchers at the GNL are internationally known for their
expertise working with pathogens including Ebola and Marburg, emerging
infectious diseases like MERS, and mosquito borne viruses like Zika and
Chikungunya. The Galveston National Laboratory is home to research that is
funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease
Control & Prevention and other federal agencies, as well as academic
partners, private foundations, and the Biopharmaceutical industry.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
During the course of the stockholder
presentation, BioLargo may make “forward-looking statements” within the meaning
of the safe harbor provisions of the United States Private Securities
Litigation Reform Act of 1995, regarding future events or the future financial
performance of the company that are subject to change. Actual results may
differ from expectations, estimates and projections and, consequently, you
should not rely on these forward-looking statements as predictions of future
events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,”
“predicts,” “potential,” “continue,” and similar expressions are intended to
identify such forward-looking statements. These forward-looking statements
involve significant risks and uncertainties that could cause the actual results
to differ materially from the expected results.
No comments:
Post a Comment